Conatus Pharmaceuticals Inc (NASDAQ:CNAT)’s share price reached a new 52-week low on Thursday after SunTrust Banks lowered their price target on the stock to $12.00. SunTrust Banks currently has a buy rating on the stock. Conatus Pharmaceuticals traded as low as $1.80 and last traded at $2.16, with a volume of 131041 shares trading hands. The stock had previously closed at $4.50.
Several other equities analysts have also weighed in on CNAT. Stifel Nicolaus lowered Conatus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a research note on Thursday. ValuEngine lowered Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 1st. HC Wainwright restated a “buy” rating on shares of Conatus Pharmaceuticals in a research note on Monday, November 5th. Finally, Oppenheimer set a $10.00 price target on Conatus Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $11.12.
Several institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $142,000. Virtu Financial LLC boosted its holdings in Conatus Pharmaceuticals by 94.6% in the 3rd quarter. Virtu Financial LLC now owns 25,860 shares of the biotechnology company’s stock worth $150,000 after buying an additional 12,572 shares during the last quarter. MYDA Advisors LLC acquired a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $154,000. LMR Partners LLP acquired a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $311,000. Finally, Paloma Partners Management Co acquired a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $547,000. Hedge funds and other institutional investors own 31.93% of the company’s stock.
The company has a debt-to-equity ratio of 0.83, a current ratio of 2.39 and a quick ratio of 2.39. The firm has a market capitalization of $136.18 million, a PE ratio of -3.54 and a beta of 1.99.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.15). Conatus Pharmaceuticals had a negative return on equity of 83.99% and a negative net margin of 52.77%. The company had revenue of $7.67 million for the quarter, compared to analysts’ expectations of $9.70 million. On average, research analysts expect that Conatus Pharmaceuticals Inc will post -0.6 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Conatus Pharmaceuticals (CNAT) Sets New 52-Week Low on Analyst Downgrade” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/12/06/conatus-pharmaceuticals-cnat-sets-new-52-week-low-on-analyst-downgrade.html.
About Conatus Pharmaceuticals (NASDAQ:CNAT)
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Read More: What are different types of coverage ratios?
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.